Interviews

Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilar rituximab may be used in cancer care.
Elaine Blais, JD, partner at Goodwin and head of the litigation department in Goodwin’s Boston office, discusses the Supreme Court’s January 2019 decision in Helsinn v Teva.
Kashyap Patel, MD, discusses the prevailing misconceptions about biosimilars among oncologists. 
Simon Rule, MD, Plymouth University Medical School, discusses the role of biosimilar rituximab in the era of subcutaneous reference rituximab in oncology. 
Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses policy challenges with biosimilars. 
Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses progress made toward the use of global reference products in biosimilar development.
C. Daniel Mullins, PhD, chair of pharmaceutical health services research at the School of Pharmacy, University of Maryland, describes the state of pharmacy school curricula related to biosimilars.
Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Danish patients are benefitting from biosimilars. 
Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, reflects on the importance of reporting new cardiac data from the LILAC trial of ABP 980, a trastuzumab biosimilar.
Daniel Mullins, PhD, chair of pharmaceutical health services research at the School of Pharmacy, University of Maryland, discusses how biosimilars are impacting the cost of care. 
 

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.